Future studies are, therefore, needed to better understand the potential utility of menin inhibitors as a therapeutic strategy to slow or even prevent the development and progression of NETs in individuals with MEN1 syndrome. This evidence concerns the gene MEN1 and multiple endocrine neoplasia type 1.